BioSpace News Archive

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2020 financial results on Tuesday, May 5, 2020, after the close of the U.S. financial markets.

Supernus Pharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, and Navitor Pharmaceuticals, Inc., a privately-held company leading the discovery and development of mTORC1-targeted therapeutics, announced a joint development and option agreement for Navitor’s mTORC1 activator, NV-5138.

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release first quarter 2020 financial results after market close on Tuesday, May 5, 2020.

Quidel Corporation, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report first quarter 2020 financial results after market close on Wednesday, May 6, 2020.

VBI Vaccines Inc., a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced that it has commenced an underwritten public offering of its common shares.

Banner Life Sciences LLC (Banner), a privately held specialty pharmaceutical company, announced today that the United States Court of Appeals for the Federal Circuit has upheld the United States District Court for the District of Delaware’s decision that Banner’s BAFIERTAM™ product does not infringe the extended portion (under the Hatch-Waxman Act) of U.S. Patent Number 7,619,001 (the “‘001 patent”) which protects Biogen’s product Tecfidera®.

Nexus Pharmaceuticals announced today it has received U.S. Food and Drug Administration (FDA) approval for its patent-pending New Drug Application (NDA) Emerphed, the first and only premixed ephedrine in a ready-to-use 50 mg/10 mL vial.

Harbour BioMed announced first patient dosing in a Phase 1b/2a study of its anti-FcRn antibody, batoclimab, for the treatment of neuromyelitis optica spectrum disorder.

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that on March 17, 2020 the United States Patent and Trademark Office issued Patent No. 10,588,927 B

Proceeds to Fund Advancement of Programs Addressing Acute Lung Injury Due to COVID-19 and Severe Birth Asphyxia (HIE)